Sun Pharma Adv. Res

July 13 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:

• SUN PHARMA ADVANCED RESEARCH - APPOINTS ANIL RAGHAVAN AS MD AND CEO EFFECTIVE AUGUST 11

Source text: [ID:]

Further company coverage: SPRC.NS

(([email protected];;))

Sun Pharma Advanced Research Company announced the retirement of Dr. Nitin Dharmadhikari, Chief Operating Officer, and Ms. Shanta Gupta, Functional Head of Human Resources, effective June 30, 2026. The company appointed Mr. Prasanna Deshmukh as the new Functional Head of Human Resources from July 1, 2026. Mr. Deshmukh previously worked at Sun Pharmaceutical Industries as an HR business partner.

Powered by Tijori

** Shares of India's Sun Pharma Advanced Research SPRC.NS jump 6.84% to 173.32 rupees

** Clinical-stage biopharma co posted a fourth quarter profit of 17.61 billion rupees ($182.8 million), compared to loss of 804.2 million rupees in Q3

** Co's total revenue jumped 68% y/y to 18.53 billion rupees

** Trading vols at 12.47 million shares, about 4 times the 30-day average of 3.28 million shares

** YTD stock jumped 20.7%

($1 = 96.3325 Indian rupees)

(Reporting by Surbhi Misra in Bengaluru)

(([email protected] | X: https://twitter.com/SurbhiMisra_ |;))

May 18 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:

• SUN PHARMA ADVANCED RESEARCH MARCH-QUARTER CONSOL PROFIT 17.61 BILLION RUPEES

• SUN PHARMA ADVANCED RESEARCH MARCH-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 18.53 BILLION RUPEES

Source text: [ID:]

Further company coverage: SPRC.NS

(([email protected];;))

April 30 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:

• SUN PHARMA ADVANCED RESEARCH - ANNOUNCES SALE OF PRIORITY REVIEW VOUCHER FOR USD 195 MILLION

Source text: ID:nnAZN4STKGC

Further company coverage: SPRC.NS

(([email protected];))

Feb 3 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:

• SPARC RECEIVES FDA PRIORITY REVIEW VOUCHER FOR SEZABY APPROVAL

• INTENDS TO UTILIZE VOUCHER TO FURTHER ACCELERATE ITS PIPELINE

Source text: ID:nBSEbNGrYK

Further company coverage: SPRC.NS

(([email protected];;))

Jan 14 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:

• SUN PHARMA ADVANCED RESEARCH - ISSUE PRICE 155.80 RUPEES PER WARRANT

Source text: ID:nNSE8GN0z

Further company coverage: SPRC.NS

(([email protected];))

Jan 8 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:

• OVERALL WORKFORCE TO REDUCE BY 40%, WITH DECREASE IN US HEADCOUNT OF MORE THAN 80%

• FINALIZING RESOURCING PLAN FOR FY27,FY28 INVOLVING ADDITIONAL PROMOTER SUPPORTED DEBT, INTERNAL CASH ACCRUALS

Further company coverage: SPRC.NS

(([email protected];))

** Sun Pharma Advanced Research SPRC.NS jumps 15% to 154.06 rupees; set for best day since January 2024

** Co says U.S. District Court granted summary judgment in favour of co in matter of issuance of Priority Review Voucher (PRV) associated with approval of Sezaby for treatment of neonatal seizures

** Adds court held USFDA's withholding of PRV was contrary to law because no drug product containing phenobarbital sodium was "previously approved" as that term is used in the statute

** More than 13.8 million shares traded, ~22.4x the 30 day avg

** YTD, SPRC down 28.2%

(Reporting by Mridula Kumar in Bengaluru)

(([email protected];))

Nov 20 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:

• SUN PHARMA ADVANCED RESEARCH - FDA DID NOT RAISE CONCERNS ON PDP-716 EFFICACY OR SAFETY

Source text: ID:nBSE7nKD5c

Further company coverage: SPRC.NS

(([email protected];;))

May 12 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:

• TO CONSIDER FUND RAISING PROPOSAL

Source text: ID:nBSE46XLR

Further company coverage: SPRC.NS

(([email protected];;))

March 31 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:

• SPARC SUBMITS IND APPLICATION FOR SBO-154 TO USFDA

• GLOBAL PHASE 1 STUDY PLANNED FOR SBO-154 IN SOLID TUMORS

Source text: ID:nBSE9gDy0x

Further company coverage: SPRC.NS

(([email protected];;))

Dec 17 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:

• SPARC SIGNS BINDING LOI WITH UCSF AND TILLER THERAPEUTICS

• SPARC TO RECEIVE 55% EQUITY IN TILLER THERAPEUTICS

• LOI FOR PRE-CLINICAL ONCOLOGY ASSET, ASSOCIATED INTELLECTUAL PROPERTY

Source text: ID:nBSE9Cy21m

Further company coverage: SPRC.NS

(([email protected];;))

** Shares of Sun Pharma Advanced Research Co SPRC.NS fall 4.7% to 205.80 rupees

** The clinical-stage biopharmaceutical co's Q2 consol loss widened to 1.07 bln rupees ($12.7 mln) vs loss of 864.2 mln rupees a year ago, revenue down 39% Y/Y

** SPRC set to snap five-session winning streak

** Trading vols 1.9x the 30-day average

** Stock down ~28% YTD

($1 = 84.1125 Indian rupees)

(Reporting by Vijay Malkar)

(([email protected];))

Adds Novo Holdings comment in paragraph 7

By Jody Godoy and Maggie Fick

NEW YORK, Oct 18 (Reuters) - U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, the controlling shareholder of Novo Nordisk NOVOb.CO, from acquiring contract drug manufacturer Catalent CTLT.N, saying the deal threatens competition in weight loss drugs and cutting-edge gene therapies.

U.S. Public Interest Research Group, Service Employees International Union (SEIU) and others expressed concerns in a letter to the FTC about the $16.5 billion deal, which Novo Holdings has said would boost supply of Wegovy, Novo's blockbuster GLP-1 injectable weight-loss drug.

Last week, U.S. Senator Elizabeth Warren, a Democrat, called on the FTC to look closely at the deal over similar concerns.

The deal could constrain options for competitors such as Amgen AMGN.O, Pfizer PFE.N, Roche ROG.S, and AstraZeneca AZN.L, who are reportedly developing their own GLP-1 drugs, the groups said.

"Because of the proposed acquisition, there is a real question of whether these future rivals to Novo will be able to secure the expertise to bring the product to market and have available and qualified capacity to manufacture these products when they commercially launch," the groups said.

Viking Therapeutics VKTX.O, Structure Therapeutics GPCR.O and Sun Pharma SUN.NS also have GLP-1 drugs in development and could be affected, the groups said.

Novo Holdings, in a statement to Reuters on Friday in response to the consumer groups' letter, said: "We remain confident in the pro-competitive rationale for this transaction and are committed to realizing the benefits it will bring to customers, and patients, and the local communities which Catalent now serves."

A Catalent spokesperson reiterated the company's position on the deal in a statement on Friday to Reuters in response to the letter: "Novo Holdings’ pending acquisition of Catalent will further strengthen Catalent’s ability to deliver better outcomes for our customers and the patients they serve."

A Viking spokesperson declined to comment. A Roche spokesperson declined to comment on the letter, but said that the drugmaker has secured near-term supplies for its clinical trials of the GLP-1 drugs it is developing. Roche plans to manage the scaling up of commercial production "by using a mix of in-house and external manufacturing", the spokesperson said.

The other companies did not immediately respond to requests for comment on Thursday.

According to the terms of the deal, Novo Holdings would sell three of Catalent's factories, where injection pens are filled in sterile conditions, in Italy, Belgium and the United States, on to Novo Nordisk for $11 billion.

Novo Nordisk has said it is committed to honoring existing contracts at the plants, and that it is not aware of any competitive GLP-1 products being manufactured for commercial sale at the three sites.

"We have and will continue to work closely with the FTC and EU regulators as intended under the law. We still expect the transaction to close toward the end of the calendar year," Novo Nordisk said in its response to the consumer groups' letter.

The groups, which included Consumer Action, diabetes group Beta Cell Action, Doctors for America and the American Federation of State, County and Municipal Employees (AFSCME) union, also expressed concern that Novo Holding's ownership could affect Catalent's capacity to manufacture gene therapies.

AFSCME represents around 1.6 million public sector workers, and SEIU has around 2 million members who work in healthcare, the public sector and property services.

Ten consumer groups had signed on to the letter on Thursday afternoon.

"The competitive concerns here go far beyond existing drugs. We believe the commission should look at the impact on future therapies including gene therapy," said David Balto, the antitrust lawyer who represents the groups and drafted the letter.

The letter mentioned Catalent's contracts with Sarepta Therapeutics SRPT.O, to produce its gene therapy Elevidys, and with Novartis NOVN.S, to produce its gene therapy Zolgensma. The Catalent facilities involved are separate from the three factories that Novo Holdings plans to sell on to Novo Nordisk.

Sarepta does not anticipate any impact from the Catalent acquisition, spokesperson Tracy Sorrentino said on Thursday. Sarepta's contract with Catalent runs through 2028.

A Novartis spokesperson said on Thursday that Zolgensma is no longer manufactured at any Catalent facility.

(Reporting by Jody Godoy in New York and Maggie Fick in London; Editing by Tomasz Janowski, Louise Heavens and Mark Potter)

(([email protected];))

By Jody Godoy, Maggie Fick

NEW YORK, Oct 17 (Reuters) - Five U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Nordisk's NOVOb.CO controlling shareholder from acquiring contract drug manufacturer Catalent CTLT.N, saying the deal threatens competition in weight loss drugs and cutting-edge gene therapies.

U.S. Public Interest Research Group, Service Employees International Union (SEIU) and others expressed concerns in a letter to the FTC about the $16.5 billion deal, which Novo Holdings has said would boost supply of Wegovy, Novo's blockbuster GLP-1 injectable weight loss drug.

Last week, U.S. Senator Elizabeth Warren, a Democrat, called on the FTC to look closely at the deal over similar concerns.

The deal could constrain options for competitors such as Amgen AMGN.O, Pfizer PFE.N, Roche ROG.S, and AstraZeneca AZN.L, who are reportedly developing their own GLP-1 drugs, the groups said.

""Because of the proposed acquisition, there is a real question of whether these future rivals to Novo will be able to secure the expertise to bring the product to market and have available and qualified capacity to manufacture these products when they commercially launch," the groups said.

Viking Therapeutics VKTX.O, Structure Therapeutics GPCR.O and Sun Pharma SUN.NS also have GLP-1 drugs in development and could be affected, the groups said.

According to the terms of the deal, Novo Holdings would sell three of Catalent's factories, where injection pens are filled in sterile conditions, in Italy, Belgium and the United States, on to Novo Nordisk for $11 billion.

Novo Nordisk has said it is committed to honoring existing contracts at the plants, and that it is not aware of any competitive GLP-1 products being manufactured for commercial sale at the three sites.

The groups, which included Consumer Action, Doctors for America and the American Federation of State, County and Municipal Employees (AFSCME) union, also expressed concern that Novo Holding's ownership could affect Catalent's capacity to manufacture gene therapies.

AFSCME represents around 1.6 million public sector workers, and SEIU has around 2 million members who work in healthcare, the public sector and property services.

"The competitive concerns here go far beyond existing drugs. We believe the commission should look at the impact on future therapies including gene therapy," said David Balto, the antitrust lawyer who represents the groups and drafted the letter.

The letter mentioned Catalent's contracts with Sarepta Therapeutics SRPT.O, to produce its gene therapy Elevidys, and with Novartis NOVN.S, to produce its gene therapy Zolgensma. The Catalent facilities producing these therapies are separate from the three factories that Novo Holdings plans to sell on to Novo Nordisk.

(Reporting by Jody Godoy in New York and Maggie Fick in London; Editing by Nick Zieminski)

(([email protected];))

June 5 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:

• CESSATION OF CHETAN RAJPARA AS CHIEF FINANCIAL OFFICER

Source text for Eikon: ID:nNSE5FqJMQ

Further company coverage: SPRC.NS

(([email protected];;))

May 24 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:

• SUN PHARMA ADVANCED RESEARCH - CHETAN RAJPARA RESIGNS AS CFO

Source text for Eikon: [ID:]

Further company coverage: SPRC.NS

(([email protected];;))

April 10 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:

• SPARC ANNOUNCES RESULTS FROM PLANNED INTERIM ANALYSIS OF PROSEEK STUDY OF VODOBATINIB IN PATIENTS WITH EARLY PARKINSON'S DISEASE

• SPARC HAS DECIDED TO CLOSE ONGOING PROSEEK STUDY

• SPARC HAS REVIEWED DATA AND DETERMINED THAT STUDY HAS NOT SHOWN EVIDENCE OF TREATMENT BENEFIT IN PATIENTS RECEIVING VODOBATINIB

• DECIDED TO CLOSE STUDY

• PLANS TO COMPLETE FULL ANALYSIS OF CLINICAL OUTCOMES AND CORRELATIVE BIOMARKER DATA IN COMING MONTHS

Source text for Eikon: ID:nBSEbzwBd0

Further company coverage: SPRC.NS

(([email protected];))

** Shares of bio-pharma co Sun Pharma Advanced Research SPRC.NS rise as much as 10% to hit upper circuit at 423.35 rupees

** Stock hits highest level since June 15, 2018

** Over 500,000 shares traded in two separate block deals priced between 422.80 and 423.35 rupees apiece - LSEG

** More than 5.6 mln shares change hands by 12:34 p.m. IST, 1.7x of 30-day avg

** Stock has been active this week with more than 5 mln shares trading daily in four out of five sessions compared with 10 sessions in whole of 2023

** Stock has risen 47.6% so far this week, best weekly gains since January 2015

** In 2023, stock rose 37.5%, best yearly performance since 2021

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

Dec 4 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:

• SUN PHARMA CANADA LAUNCHES (PR)ABSORICA LD® (ISOTRETINOIN CAPSULES) FOR TREATMENT OF SEVERE ACNE

Source text for Eikon: ID:nCNWlk5tYa

Further company coverage: SPRC.NS

(([email protected];))

** Shares of Sun Pharma Advanced Research SPRC.NS rise as much as 8% to 277.85 rupees, highest since April 22, 2022

** Stock on track to post highest monthly gain since May 2021, if trends hold

** Stock has been above its 50-day, 100-day, and 200-day simple moving avgs of since Nov. 9, indicating bullish sentiment

** Trading vol is 5.1x the 30-day daily avg, tops 6 mln for the first time since Nov. 9

** SRPC traded most since Aug. 30

** Stock up 7% as of 10:47 a.m. IST, extending YTD gains to ~32%

(Reporting by Anuran Sadhu in Bengaluru)

(([email protected] ;))

** Shares of Sun Pharma Advanced Research Company SPRC.NS up as much as 7.67% to 247.15 rupees, their highest since Sept. 15

** Bio-pharma co hits sharpest intraday pct gain since Oct. 18

** SPRC enters into an licence agreement with Johns Hopkins University and The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences

** Agreement to exclusively license SCD-153 Alopecia Areata drug

** About 3.3 mln shares traded as of 12:07 p.m. IST, 4.7 the 30-day average

** Stock last up 5.1%, extending YTD gains to ~15%

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

Sept 26 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:

• INCORPORATED UNIT IN DELAWARE, US

• COST OF ACQUISITION $50,000

Source text for Eikon: ID:nBSEc4DkjC

Further company coverage: SPRC.NS

(([email protected];))

** Shares of Sun Pharma Advanced Research Co SPRC.NS rise as much as 4.5% to 230.9 rupees

** Co said on Thurs that US FDA issued a Complete Response Letter for application of glaucoma treatment, PDP-716

** Says FDA did not raise any issues with PDP-176's clinical efficacy or safety and no additional data or trials requested

** Trading vol already at 0.5X the 30-day daily avg as of 9:38 a.m. IST

** Stock up almost 6% YTD as of last close

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))

July 13 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:

• FDA ISSUES COMPLETE RESPONSE LETTER FOR PDP-716 NDA DUE TO INSPECTION FINDINGS AT 3RD-PARTY API MANUFACTURING FACILITY

• NO ISSUES WITH CLINICAL EFFICACY OR SAFETY WERE IDENTIFIED IN CRL

• NO ADDITIONAL CLINICAL DATA OR TRIALS HAVE BEEN REQUESTED

Further company coverage: SPRC.NS

(([email protected];))

** Shares Sun Pharma Advanced Research Co Ltd SPRC.NS down as much as 7.25% to 180.3 rupees, their lowest since April 5

** Stock posts worst intraday pct loss since Feb. 14, on track for third consecutive session of decline if trends hold

** SPRC reported a widened Q4 loss of 819.9 mln rupees ($10 mln), versus loss 710.5 mln rupees a year ago

** About 2.4 million shares change hands as of 2:39 p.m. IST, 3.7x 30-day average

** Stock extends YTD fall to 11.7%, from 6.81% at last close

($1 = 81.7800 Indian rupees)

(Reporting by Manvi Pant in Bengaluru)

(([email protected];))

May 17 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:

• WILL ALSO CONSIDER PROPOSALS FOR RAISING FUNDS

Source text for Eikon: ID:nBSE35P4cT

Further company coverage: SPRC.NS

(([email protected];))